Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 12/20 | 0.51 |
| ▸ | FNTB | P49356 | 11/20 | 0.51 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | MC4R | P32245 | 2/20 | 0.32 |
| ▸ | MC1R | Q01726 | 2/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5131468 | 1.00 | FNTA (0.51) | FNTAFNTBPGGT1BCYP19A1GRM2 | |
| Hydrochloric Acid SCHEMBL8160943 | 0.99 | FNTA (0.51) | FNTAFNTBPGGT1BCYP19A1GRM2 | |
| Hydrochloric Acid SCHEMBL8541088 | 0.99 | FNTA (0.51) | FNTAFNTBPGGT1BCYP19A1GRM2 | |
| SCHEMBL3687066 | 0.94 | FNTA (0.59) | FNTAFNTBPGGT1BCYP19A1GRM2 | |
| SCHEMBL445626 | 0.94 | FNTA (0.59) | FNTAFNTBPGGT1BCYP19A1GRM2 | |
| SCHEMBL8147489 | 0.90 | FNTA (0.48) | FNTAFNTBPGGT1BCYP19A1GRM2 | |
| Trifluoroacetic Acid SCHEMBL8147178 | 0.89 | FNTA (0.54) | FNTAFNTBPGGT1BCYP19A1MC4R | |
| SCHEMBL4405093 | 0.84 | FNTA (0.40) | FNTAFNTBPGGT1BCYP19A1GRM2 | |
| SCHEMBL3682663 | 0.84 | FNTA (0.48) | FNTAFNTBPGGT1BCYP19A1NR1H4 | |
| SCHEMBL3499540 | 0.84 | FNTA (0.48) | FNTAFNTBPGGT1BCYP19A1NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 448 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140301976-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. | 2014-10-09 | — | — | US | claimed |
| US-8779171-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2014-07-15 | — | — | US | claimed |
| US-20130142758-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2013-06-06 | — | — | US | claimed |
| US-6989383-B1 | Method of treating cancer | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2006-01-24 | — | — | US | claimed |
| US-20050277629-A1 | Methods for the treatment of synucleinopathies (Lansbury) | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-12-15 | — | — | US | claimed |
| US-20030220241-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2003-11-27 | — | — | US | claimed |
| JP-2001524079-A | — | — | 2001-11-27 | — | — | JP | claimed |
| EP-0973396-A4 | A METHOD OF TREATING CANCER | MERCK & CO INC (US) | 2001-02-07 | — | — | EP | claimed |
| WO-2000059930-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2000-10-12 | — | — | WO | claimed |
| WO-2000025789-A1 | A METHOD OF TREATING ENDOMETRIOSIS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | claimed |
| EP-0986302-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2000-03-22 | — | — | EP | claimed |
| EP-0973396-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2000-01-26 | — | — | EP | claimed |
| WO-1998054966-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1998-12-10 | — | — | WO | claimed |
| WO-1998044797-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1998-10-15 | — | — | WO | claimed |
| EP-0820445-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-01-28 | — | — | EP | claimed |
| WO-1996030343-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-10-03 | — | — | WO | claimed |
| US-20260000691-A1 | COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT | JENNINGS BARBARA BROOKE (US) | 2026-01-01 | — | — | US | disclosed |
| US-12329766-B2 | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development | JENNINGS BARBARA BROOKE (US) | 2025-06-17 | — | — | US | disclosed |
| EP-0820445-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-01-28 | — | — | EP | disclosed |
| WO-1996030343-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220241-A1 | Method of treating cancer | ACP3, PSAT1, LCAT | FNTA 4/4885FNTB 19/4885PGGT1B 274/4885 |
| US-20130142758-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | FNTA 3317/4885FNTB 1753/4885PGGT1B 715/4885 |
| US-20260000691-A1 | COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT | PDK1, IP6K1, IP6K3 | FNTA 3572/4885FNTB 2992/4885PGGT1B 3876/4885 |
| US-20140301976-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | FNTA 3317/4885FNTB 1753/4885PGGT1B 715/4885 |
| US-20050277629-A1 | Methods for the treatment of synucleinopathies (Lansbury) | SNCA, PARK7, NLN | FNTA 12/4885FNTB 44/4885PGGT1B 1996/4885 |
| US-12329766-B2 | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development | PDK1, PKM, PDK2 | FNTA 3930/4885FNTB 2686/4885PGGT1B 4596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.